Loading…
← CockpitCompetitor Analysis › DRTS Alpha Tau Medical LtdOpen in the cockpit ↗

Alpha Tau Medical LtdDRTSCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties

Israeli medical device company developing Alpha DaRT, a radiation therapy using alpha particles to treat solid tumors.

≈ An early-stage alpha-radiation cancer therapy companyMomentum neutral 43
Mkt cap
$1.11B
US dollars, full cap
Free float
80%
of shares outstanding
$/day
$8.02M
20-day average traded
P/B
25.17×
price to book
ROE
-141.7%
delivered
Implied ROE
216.8%
what the price asks
Next earnings
6 days
24 Nov 2026
Close · USD$12.01
1D-0.7%
1W-14.3%
1M-8.2%
3M-16.4%
6M+7.4%
YTD+142.6%
1Y+215.2%
ATR %6.5%
Beta2.08
52w lowhigh23.9% off high

What Alpha Tau Medical does

Israeli medical device company developing Alpha DaRT, a radiation therapy using alpha particles to treat solid tumors.

No widely sold product yet, so it is funded by cash raised from investors and spends it on clinical trials and on building up production of its radioactive sources. Regulatory approvals in each country decide when sales can begin. It went public through a 2022 merger with a blank-cheque company.

In one line: An early-stage alpha-radiation cancer therapy company.

Products and services

  • Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy)
  • Clinical trial programs across tumor types

Customers

  • Radiation oncologists
  • Cancer patients (skin, head/neck and other solid t

Where it sits in the supply chain

  • Medical devices
  • Oncology radiotherapy
  • Alpha-particle brachytherapy for solid…

What could go right

  • Expanding trial indications/approvals
  • Partnership/licensing deals with device makers

What could go wrong

  • Early-stage/no major approved product yet
  • Clinical trial and regulatory risk

Moat: narrow (IP / patents). Patented alpha-particle radiation technology offers a novel localized cancer treatment approach.

Headquarters: Jerusalem, Israel · Founded: 2016 · Employees: 112

Named competitors

Alpha Tau Medical at a glance

Size Alpha Tau Medical (DRTS) is a United States Health Care company (Medical Specialties) with a market value of $1.11B, the 2162nd largest of 3,085 United States companies the cockpit tracks. Shares closed at $12.01 on 18 Nov 2026.

Performance Over six months the shares gained 7.4%, against -9.9% for the median peer and -2.2% for the United States market (cap-weighted) — 6th highest of 20 in its peer set.

Valuation It trades at 25.17× book value against a peer median of 3.08× (3rd most expensive of 21).

Price implies The share price implies a return on equity of about 216.8%; Alpha Tau Medical delivers -141.7%, so the price asks more than the business earns today.

Next results Next results expected around 24 Nov 2026 (exchange calendar; dates can move).

Relative performance

8010012014021 May 202621 Aug 202618 Nov 2026DRTS 110Peer median 88
Six months, rebased to 100: Alpha Tau Medical against the median of its 20 peers (local-currency closes).

Alpha Tau Medical financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$0$0$0$0$0
Revenue growth—————
Gross profit$0-$1.23M-$1.10M-$1.07M-$979,000
EBITDAn/a-$41.1M-$34.9M-$34.6M-$31.2M
Net income-$92.6M-$42.6M-$31.8M-$29.2M-$33.8M
Free cash flown/a-$32.8M-$22.0M-$24.4M-$24.8M
Capital expendituren/a$6.08M$2.24M$6.40M$904,000
Total debt$15.2M$13.7M$12.5M$13.3M$5.19M

Quarterly statements and history in the cockpit →

Alpha Tau Medical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%+20%ATEC300406214150IART688161301101688622SIBNIRMDTNDMCSTLEUZ60005530102165232675300685300206DRTS6-month return →1-month return →
Up and to the right = strong over both horizons. Alpha Tau Medical is the large dot.

Fundamentals: return on equity against price-to-book

-150%-100%-50%0%00×100×200×ATEC300406FRNMIART301101688622SIBNIRMDTNDM6000556523DRTSReturn on equity →Price / book →
A bank or insurer earning more on its equity usually trades at a higher multiple of book; points far above the trend are priced for more. Alpha Tau Medical is the large dot.

Capital: ROE delivered against the ROE the price implies

-100%0%100%200%-100%0%100%200%300406FRNM688622SIBNIRMDTNDM301021DRTSROE delivered →ROE the price implies →
Above the diagonal = the price asks for a higher return on equity than the business earns today. Alpha Tau Medical is the large dot.

Alpha Tau Medical competitors and peer comparison

Head to head with its named competitors (DRTS vs SHL.DE vs EKTA-B.ST vs ARAY)
CompanyMarket cap6M returnRevenue growthROEPrice / bookImplied ROE
Alpha Tau Medical DRTS$1.11B+7%n/a-142%25.17×216.8%
Siemens Healthineers SHL.DE$53.7B+27%+1%12%n/an/a
Elekta EKTA-B.ST$2.35B0%-7%-4%3.16×21.4%
Accuray ARAYn/a-81%n/an/an/an/a

How Alpha Tau Medical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Alpha Tau Medical against its 20 peers (data as of 18 Nov 2026)
MeasureDRTSPeer medianRank in peer set
1-month return-8.2%-4.7%7th lowest of 21
6-month return+7.4%-9.9%6th highest of 20
Return on equity-141.7%7.2%2nd lowest of 21
Price / book25.17×3.08×3rd most expensive of 21
ROE the price implies216.8%21.9%most demanding of 20
ROE delivered-141.7%7.2%2nd lowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthROEPrice / bookImplied ROEDelivered ROE
Alpha Tau Medical DRTSUnited States$1.11B+7%n/a-142%25.17×216.8%-141.7%
Alphatec ATECUnited States$1.10B-14%+15%-308%85.37×n/a-308.1%
Beijing Strong Biotechnologies 300406.SZChina$1.13B-4%-4%7%2.08×13.0%6.6%
Freenome FRNMUnited States$1.08Bn/an/a21%2.24×14.2%20.8%
CLASSYS 214150.KSSouth Korea$1.08B-60%+16%21%2.58×11.0%20.7%
Integra LifeSciences IARTUnited States$1.08B-10%+1%1%1.01×11.6%1.2%
Shandong Weigao Orthopaedic Device 688161.SSChina$1.14B-29%-6%6%1.81×13.6%5.8%
Mingyue Optical Lens 301101.SZChina$1.07B-4%+14%12%3.86×23.9%12.4%
Guangzhou Hexin Instrument 688622.SSChina$1.06B+21%-29%-27%25.84×200.6%-27.4%
SI-BONE SIBNUnited States$1.06B+59%+14%-8%5.74×33.2%-7.7%
IRadimed IRMDUnited States$1.05B-9%+11%23%9.89×68.5%23.4%
Tandem Diabetes Care TNDMUnited States$1.19B+13%+7%-37%8.80×91.5%-36.7%
Castle Biosciences CSTLUnited States$1.03B+67%+10%-5%2.15×18.2%-4.9%
Eckert & Ziegler EUZ.DEGermany$1.03B-2%+4%21%3.30×30.1%21.1%
Beijing Wandong Medical Technology 600055.SSChina$1.03B-26%-11%-8%1.60×11.3%-7.7%
Inno Laser Technology 301021.SZChina$1.03B-33%+17%8%6.36×86.7%7.8%
PHC 6523.TJapan$1.02B+34%+3%9%0.96×8.3%9.1%
Shenzhen Edge Medical 2675.HKHong Kong$1.21B-51%+132%-1%3.56×21.9%-1.1%
Eyebright Medical Technology (Beijing) 688050.SSChina$1.21B-16%+21%8%2.72×17.2%8.4%
Amoy Diagnostics 300685.SZChina$1.01B-15%+7%18%3.40×28.0%17.6%
Edan Instruments 300206.SZChina$1.00B-19%+14%16%2.86×25.6%16.5%

Questions

Who are Alpha Tau Medical's main competitors?
Named competitors: Siemens Healthineers (Varian) (SHL.DE), Elekta AB (EKTA-B.ST), Accuray (ARAY). The cockpit's measured peer set (industry) also includes Alphatec (ATEC), Beijing Strong Biotechnologies (300406.SZ), Freenome (FRNM), CLASSYS (214150.KS), Integra LifeSciences (IART), Shandong Weigao Orthopaedic Device (688161.SS).
Is Alpha Tau Medical expensive compared with its peers?
On price / book it trades at 25.17× against a peer median of 3.08×, 3rd most expensive of 21 in its peer set. The share price implies a return on equity of about 216.8%; Alpha Tau Medical delivers -141.7%, so the price asks more than the business earns today.
How has Alpha Tau Medical stock performed?
Over six months to 18 Nov 2026 the shares returned +7.4% against -9.9% for the median peer; over one year +215.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.